This suggests that, in tumor cells with high Mcl-1 dependency, a rationally devised combination treatment targeting Mcl-1, as well as single-agent Mcl-1 inhibitors, may trigger cell death in breast cancer [7]. The gene discussed is MCL1; the disease is neoplasm.